Home / Transcripts / Arkema S.A. (AKE) · November 5, 2026

Arkema S.A. (AKE) Earnings Call Transcript

November 5, 2026

Euronext Paris FR Materials Chemicals earnings 46 min

Earnings Call Speaker Segments

Operator operator
#1

Good morning. I’m the conference operator. Welcome, and thank you for being with us on the Arkema third quarter 2026 results and outlook conference call. Thank you. Please note that everyone attending is in listen-only mode. Following the presentation, you’ll have a chance to ask questions by pressing star 1 at any time. If anyone requires assistance during this conference call, they can signal an operator by pressing star and zero on their telephone. At this point, I’d like to hand the conference over to Mr. Thierry Le Henaf, Chairman and Chief Executive Officer. Please go ahead.

Speaker unknown
#2

Thank you, and good morning to everyone. Welcome to the conference call covering Arkema's Q3 26 results. Joining me on this call are Marie-Josée Doncion, our CFO, along with the Investor Relations Team. As usual, we've posted a set of slides to accompany this call, and you can find them on our website. I'll begin with a few remarks on the quarter's highlights, and then I'll hand things over to Marie-Josée, who will take you through the financials. Once the presentation wraps up, we'll be glad to take your questions. So let's begin by looking at the macroeconomic conditions we faced during the third quarter, which continue to be challenging. Oil and raw material prices, along with energy and logistics costs, climbed sharply during the summer following renewed tensions in the Middle East. Overall demand was soft, and Europe showed no signs of recovery. After several quarters of strong growth, Asia decelerated, especially China, while the US posted better demand than in last year's Q3. So against this backdrop, which was largely challenging, Arkema turned in an overall quite solid performance, though it varied by region and by product line. In Q3, sales rose materially, up 8% year-on-year, helped by the price effect and driven in particular by North America, where our well-established footprint benefits us and which represented roughly 36% of group sales in Q3.

Speaker unknown
#3

Apologies for that. On volume, the effect was marginally favorable, with specialty materials turning in a healthy 1.7% gain in volume. On top of that, we lifted EBITDA by 7% to €330 million — a meaningful improvement that once more underscores the caliber of our portfolio and how resilient both our top line and our profitability are in a demanding environment. On top of that, we lifted EBITDA by 7% to €330 million — a meaningful improvement that once more underscores the caliber of our portfolio, along with the resilience of both our top line and our profitability in a demanding environment. Our results were especially strong given the negative effect of the Middle East conflict during Q3 and the lack of the acrylic support that we had in Q2. Our EBITDA margin holds steady at 14%. That is a solid outcome when you consider that the dilution from pricing tied to inflation comes to roughly 1%. I also want to emphasize that adjusted earnings per share rose 23% versus last year. Above all, that entire earnings increase originated in our specialty materials, which sit at the core of our strategy and now account for 90% of Group EBITDA. So, when we look at the specialty material segment, adhesive and coating solution posted especially robust results.

Speaker unknown
#4

That was thanks to a richer product mix. To be more specific, Adhesive Solutions was the top performer, posting a 39% increase in EBITDA and building on the positive momentum from Q2. Support came from the strength in industrial adhesives and faster growth in higher value added solutions — particularly adhesives for durable goods in aerospace transportation and industrial application — while demand in construction is still subdued. EBITDA for Coating Solution rose by more than 20%, extending the positive Q2 dynamic in the more downstream businesses, namely UV curing application and rheology additives. Advanced material was roughly flat, helped by our new business development in high-performance polymer, while performance additives keep suffering because of the situation in the Middle East. On the back of this specialty materials performance, we keep speeding up commercialization of high-value-added solutions in attractive markets such as batteries, water management, and adhesive for durable goods. Consequently, our EBITDA keeps gaining from the shift in our product mix. We also keep benefiting from the ramp-up of our major projects, which should add €50 million of EBITDA in 2026 versus last year. With PVDF still growing, the new capacity in the U.S. that started at the end of Q2 arrived at just the right moment.

Speaker unknown
#5

Our new Rilsan clear transparent polyamide unit in Singapore follows the same pattern — it has seen robust expansion since the beginning of the year. During Q3, we stay sharply focused on the things within our control. Slide number four shows that we remain on course to counter fixed-cost inflation by year-end, with €55 million in cost savings delivered year-to-date. Head count is also moving in the right direction: we achieved a reduction of more than 2% by end September via natural attrition, without any additional separation cost. Capital allocation likewise stays highly disciplined. Working capital continues to be tightly managed, and CapEx remains under strict control. Marie-Josée will go into this in more detail. We apply the same discipline to pricing, taking the action required to counter raw material inflation and, more recently, the sharp increase in energy costs, especially in Europe. To date, we have succeeded in offsetting these inflationary pressures. On energy costs, slide number five illustrates that our portfolio is significantly less energy intensive than that of our European peers. Beyond that, our exposure to non-carbon energy sources is much higher. We gain, for instance, from our biomethane supply contract in adhesive solution and from the 20% gain in energy efficiency at our Carling site.

Speaker unknown
#6

Regarding our top line, our attention is entirely on markets with high growth that global megatrends are driving. This is an area where Arkema truly stands out as a powerful differentiator, uniting our know-how in bonding and protecting materials so that innovation speeds up and fresh opportunities open up. Bio-based adhesives and battery are excellent illustrations. In battery specifically, pulling technology together from across our segments lets us provide more integrated solutions and greater value to top manufacturers. This strategy has innovation at its core. Our growing R&D center in Shanghai and battery center of excellence in France are going to speed up innovation in key growth markets and draw us even nearer to our customers. Arkema is turning into an innovation-driven company more than ever before, and that ambition sits side by side with sustainability, as the recent validation of our net zero target by SBTI Services illustrates. In a world that grows more volatile and uncertain, Arkema continues to move ahead. We have carried out our strategy consistently to build a global leader in specialty materials, which now account for a notably higher share of our group EBITDA and contribute strongly to how resilient Arkema's results are. We have already traveled a long way, yet more is still to come, thanks to our well-invested asset base, our technology competencies, and strong innovation capabilities.

Speaker unknown
#7

At this point, I’ll pass things to Marie-Josée so she can walk us through the financials in greater detail, and then we’ll cover the outlook at the close of the presentation. Thank you. Thanks, Thierry. Good morning, all.

Marie-José Donsion executive
#8

I'll begin with Arkema's revenue figures. Q3 sales reached 2.4 billion euros, representing an 8.1% increase versus the prior year, mainly powered by a favorable 6% price effect that mirrors the group's continuing pricing measures throughout every business in response to inflation in raw materials and energy costs. Volumes rose 0.6% as well, even though demand was soft across the board. Each of the three segments — adhesives, advanced materials, and coating solutions — added to the 1.7% growth posted by specialty materials. Intermediary materials volumes, in contrast, fell 5.1%, mirroring sluggish acrylics demand. I should note that foreign exchange gave a positive 1.8% boost during Q3, stemming from the US dollar and Chinese yuan strengthening against the euro compared with a year earlier. Q3 EBITDA stood at €332 million, 7% higher than a year ago, and the EBITDA margin was 14.1%. As Thierry mentioned, Adhesive Solutions posted a strong quarter, with EBITDA climbing 9% year-on-year and the EBITDA margin hitting 13.7%, notwithstanding roughly 80 bps of margin dilution caused by price increases in that segment. Advanced materials recorded a modest year-on-year EBITDA improvement along with a 19% margin. This largely came from high-performance polymers, which kept gaining from appealing markets in batteries, cables, and consumer goods, particularly PVDF and PA 11.

Marie-José Donsion executive
#9

Coating Solutions turned in another robust quarter, with EBITDA climbing 23%. Additives had an especially good showing, thanks to continued expansion at Sartomer in Europe and the US, along with Rheology Additives. That better mix helped push EBITDA margin up to 12.9%. Finally, Primary Materials EBITDA fell amid softer market conditions in acrylic monomers, while old generation refrigerants posted a modest improvement. Depreciation and amortization came in at €176 million, which brought recurring EBIT to 157 million, an 11% increase, and left the REBIT margin essentially flat at 6.6%. Non-recurring items totaled €42 million, including €34 million of PPA depreciation and amortization. Financial expenses were minus €30 million, in line with last year. As a result, Q3 adjusted net income came to €3 million, equal to €1.23 per share, 23% higher than a year ago. Turning to cash flow and net debt, recurring cash flow hit €129 million, and working capital stayed firmly in check at under 17% of annualized sales. This really shows tight discipline in managing inventories and collecting cash, in a setting where inflation mechanically weighs on the value of working capital. In fact, we anticipate inflation will have a negative effect of roughly €150 million on working capital across the full year 2026.

Marie-José Donsion executive
#10

This quarter, capital expenditures came in at €110 million, which keeps us solidly on track to deliver full-year CAPEX under €600 million. As of the end of September, net debt plus hybrid bonds totals €3.5 billion, and that includes €800 million of hybrids. Right now, the ratio of net debt to EBITDA for the trailing 12 months sits at roughly 2.8 times. Thanks for listening. I'll pass it to Thierry now for the outlook.

Speaker unknown
#11

Thanks, Marie-José. As we head into Q4, we're assuming the macro picture stays tough, continuing along the same lines as the quarter just ended — meaning limited visibility and soft demand. At this point, we don't see external conditions getting any easier over the next few months. Taking the macro backdrop together with where we stand today, we're still confident we can hit our full-year guidance, with EBITDA a bit above last year's level on a constant-currency basis. If I can, I'd like to note that we gave that guidance early in the year, before the Middle East conflict broke out, and the good news is we've managed to leave it as is despite the extra headwinds. To wrap up, let me add that the earnings growth we've posted so far this year — with a richer product mix, which you can also see in Q3, and supported by our innovation and advanced customized solution — shows how our business model is becoming more resilient, and reflects the strides we're making in bolstering our financial performance. So many thanks for your attention; Marie-José and I are now happy to take your questions.

Operator operator
#12

Thank you. Speaking as the conference operator, the question-and-answer portion of the call starts now. If you'd like to pose a question, you can press star and one on your touchtone phone. Should you wish to drop out of the queue, press star and 2. When you ask your question, please lift the receiver. At this point, anyone with a question can press star and one. Our first question is from Katie Richards of Barclays. Please go ahead.

Katie Richards analyst
#13

Hello, and thanks for taking the call. My first question is this: we've begun to notice indications that construction activity in Europe is picking up, and a few companies in the sector have reported a clear improvement. Given what you've said today, would it be fair to describe your construction volumes as not yet reflecting that? And is the reason that you need the US to turn here? My second question, please, concerns PBDF. After Europe announced investigations into PBDF imports from China and some other countries, could you tell us how competitive intensity around those imports has evolved? In Europe, you've spoken before about moving toward suspension grade PVDF and away from some of the emulsion grades, where as I understand it Arkema is predominantly positioned. How far along is that transition, and have you seen it lead to better pricing or margins?

Speaker unknown
#14

Alright, Cathy, thanks for that question. So on the first one, construction in Europe — and maybe we should tackle it on a broader level — no, up to now we aren't really seeing any shift in the trends. Over in Europe, interest rates are going up. As you can see, I don't think that's helping construction. What's clear is that when we look at the businesses of ours that are most affected by, or let's say most tied to, construction — on adhesives, which truly had a strong quarter, as you could see, for us that really came out of industrial adhesives. Not construction. Construction was flattish, but certainly not recovering. Flattish, let's say, but really the growth in adhesive came out of industrial. On coatings, overall, it was a super performance in the quarter by coatings, and because overall, as we mentioned, the performance in the quarter has been driven by adhesives and coatings, but I'd say once again, and you know that we are more positioned, for both adhesives and coatings, on residential and renovation. We haven't seen any improvement so far, but on the other side, our businesses that are more industrial-related are doing very well, including with support from megatrends.

Speaker unknown
#15

Regarding PVDF, I'd rather not get too detailed. What I can tell you is that we keep achieving steady growth and robust results with PVDF globally. Our technology is something we're pleased with. Over time, we've genuinely come out ahead. Consider batteries as an illustration — LFP is expanding much more quickly than NMC, and that benefits our technology. So overall, we feel good about PVDF volumes and the direction they're heading. As for the investigation, I'd prefer not to offer any particular comment. Thank you. You're welcome.

Operator operator
#16

Our following question is from Laurent Favre at BNP. You have the floor.

Laurent Favre analyst
#17

Good morning, and thanks for taking the questions — there are two. On the first, it's about the 130 million of capex that went into Carolina, which I believe was only just finished. Could you speak to how competitive that site is at this point, and whether, in what I'd call fairly weak cycle conditions right now, it's changing the EBITDA that site produces in a meaningful way? I'm thinking something like low double digit EBITDA millions, maybe. The second one is for Marie-Josée, and it concerns CapEx. The guidance is under 600 — I think you're rating it, well, technically under 500, though I'm aware Q4 involves LAMP. Could you give us somewhat more specific CapEx guidance for this year, and also an early view on 2027? Thank you.

Speaker unknown
#18

All right, hi Laurent, and thanks for that question. So turning to Carlin — first off, there's good news, and as you were able to see in the press release, this really significant transformation of the Carlin process has worked out quite well. That means we're able today to state that the site is genuinely performing well, and it represented a breakthrough technology. So I'd say it's a good — it rewards the quality and the efforts of the team. Competitiveness, I would say, comes from a combination of 2 things: the scale and the quality of the process. Carlin rests on these 2 pillars, these 2 boxes, I'd put it, because it's a world-size, a world-scale site. And second, the process now places the Carlin site in a good position within the first quartile. So when it comes to competitiveness, it's quite competitive. Now, as you wisely pointed out, at present the acrylics condition, after a Q2 in which we had a little bit of a bump, has returned to a low cycle condition, and you know that as long as we remain in a low cycle condition, the EBITDA, I would say, is more in the single digit, as you're aware — but beyond that, this is a cyclical business, and it can generate, as we've seen in the past, a lot of cash when the cycle comes back.

Speaker unknown
#19

Right, we can confirm that up to now we've been seeing low-cycle conditions. OK. Uh… my question is on capex? Sorry… uh.

Marie-José Donsion executive
#20

On CapEx, the trend is right there for you to see. It's reasonable to say that the 20 million reduction in spend in Q3 follows reduced spending in Q1 and Q2. So cumulatively, we're now €70 million under, let's say, the CapEx spending trend of the last year. That's why we feel comfortable, let's say, confirming that we see no reason we shouldn't beat, let's say, the guidance on CapEx to be below 600 million. So I have no, let's say, further update to give regarding next year at this point.

Operator operator
#21

Thinking about the macro picture, I suppose something pretty comparable would be reasonable to expect. Thanks. Our next question is from Chetan Udeshi at JP Morgan. You have the floor.

Chetan Udeshi analyst
#22

Yes, hello, and thank you for taking my questions. There's one question I probably attempt to ask you roughly every 18 months. We're seeing a degree of acceleration when it comes to consolidation, M&A, and portfolio actions, and I know Arkema has accomplished a great deal over the last 10 years. Still, how do you view your current structure? I'm also quite curious about your adhesives business, because I recognize that the mix differs between your business and some of your peers, but when I've compared your volumes in this business, it really appears to have lagged considerably over the past seven, eight years, particularly since the COVID-19 pandemic. And why do we think — or perhaps you can help us understand — why is Arkema the best owner of this business, and why would you not consider strategic options for it, given your multiple versus some of the pure play peers in that industry as well? Thank you very much.

Speaker unknown
#23

Yes, hi Chetan. So no, I believe the response here is quite straightforward, quite evident, and plain for anyone tracking Arkema. Arkema's approach is sharply defined around specialty, and adhesives stand as a distinct pillar of the specialty materials plan, which rests on 3 pillars, One Arkema, fully integrated inside Arkema. We've generated tremendous value in adhesives. If you look at where we began, which was that excellent acquisition from Total, we've boosted profitability quite substantially. We're genuinely elevating the portfolio. There's still plenty of distance left to cover. That's great because adhesives hold boundless opportunity. This low capex fits our strategy perfectly. As everyone is aware, we intend to keep going, to keep growing adhesives, to lift the margin, to pursue acquisitions, bolt-on M&A in adhesives, and we're a very content owner in the adhesive market. The adhesive segment once more, very, very much part of the plan on 3 legs, on the raw material, we stick materials, we make materials, we coat materials, so you have the adhesive segment, you have the advanced material segment, and you have the cutting segments, but I'm certain you already know the response to that question.

Speaker unknown
#24

All right?

Chetan Udeshi analyst
#25

Understood. If I were to ask a follow-up — some of your peers, especially… actually, the majority of them appear fairly optimistic when it comes to order books and October trends, and I suppose you don't come across as equally optimistic regarding what you're observing in your divisions in terms of the order book. I'm not sure whether you'd like to perhaps provide some insight into a few of those divisions, and whether you're actually seeing any meaningful pickup in your business as we look ahead to Q4 compared with what you've witnessed over the last few quarters.

Speaker unknown
#26

I believe each person communicates in their own way. You've known us for a good many years now — some of you for 20 years. Our communication has always been cautious, and that's how we'll keep it. Still, facts are facts and results are results. I'd say the release we put out is pretty solid, and we lifted EBITDA by 7%. Incidentally, we raised EBITDA in adhesive by 9%, and that's fairly meaningful. Coming back to your adhesive question — volumes are holding up reasonably well, even measured against peers. A number of our peers are posting negative figures. So overall, we see ourselves as fairly solid and robust given where things stand today, though we're not here to tease anything. Broadly speaking, the macro picture stays difficult and inflation is present everywhere. Geopolitics is complicated, and against that backdrop I think we're performing quite well. You can see it this year, especially in Q3 — the fact that we're reaffirming our full year guidance strikes me as a positive signal, since the macro overall is certainly trickier than most would have expected. Beyond that, when the macro is the same for everyone, each person can choose a different manner of expressing it, perhaps a more cautious one.

Speaker unknown
#27

That's the approach we take, and I don't see us moving away from it.

Chetan Udeshi analyst
#28

That’s appreciated. Thank you. You’re welcome.

Operator operator
#29

Jean-Luc Romain from CIC CIB has our next question.

Chetan Udeshi analyst
#30

Mr. Romain, your line is open. Perhaps you're on mute. We can't hear you. So the next question comes from Matthew Yates with Bank of America. Please go ahead.

Matthew Yates analyst
#31

Morning, everyone. I had a few questions regarding innovation and where you're steering the company. And when you answer, please keep the chemistry gentle so I can follow along. Could you expand a bit more on rheology? Because from what you said, end coatings volumes clearly aren't all that strong. So what's behind the growth you're seeing in rheology? Is it a product you've recently launched? A regulatory shift of some kind? Customers reformulating to cut costs, or something else — could you speak to that? And second, in the presentation you mentioned PI cutting thickness down to roughly a third or so. Could you say more about what incremental opportunities and markets a thinner product like that, so to speak, opens up for you? Thank you.

Speaker unknown
#32

On rheology, if I can, I'd like to broaden that to UV curing, since that's really the heart of it. Look at coatings — a very good overall range, a very good range of resins and additives. Within that range, you truly have a product of very high value with accelerated growth, which we see in rheology but also in UV curing. And incidentally, if you look at Q3 performance, UV — this is a complete coating solution, I'd call it a business, namely UV curing, performing well growth-wise. We appreciate that. That said, our UV acrylic business, backed by electronics, 3D, medical, and semiconductor, has really sped up its growth this year. So I wanted to bring it up, because it's more, I'd say, UV curing than rheology per se. Now, rheology is a very good additive, as you know, since it changes by nature. The rheology of various additives and of our customers' product, including... including paints, but also — even if I don't want to list every application — in plenty of applications in construction, in water treatment, in mining, because, for instance, product transfer: you can achieve a great deal by changing the rheology of our customers' product, but again, I'd say that for Q3, it has come more from Sartomer UV curing products and from rheology.

Speaker unknown
#33

When it comes to Piam, I believe there's substantial demand—particularly within electronics—for miniaturizing requirements and for thermal characteristics, thermal dissipation included. Available space in every end application keeps shrinking more and more. And as you're aware, our customers don't want us to be overly specific about the application we share with them, but it truly is this idea of miniaturization, of reduced space, of light weighting—where having a field of substantially reduced thickness that still delivers constant performance, which matters a great deal, is really driving greater demand for Piam and for PI overall. Thank you, Tiara. You're welcome.

Operator operator
#34

Jaideep Panthapuram has the next question. Sandhya from On-Field Research, the floor is yours.

Jaideep Pandya analyst
#35

Thank you. My first question concerns thiochemicals. I'd simply like to understand what is going on with the legacy portion of that business, the part where you supply the methionine industry. After all, there have been announcements that CJ may shut down for good, and Evonik has clearly gone in for backward integration. So I'm curious about thiochemicals as a business unit — what is actually taking place there. My second question really centers on the acrylics market. You rightly point out that once the market comes back, this is a highly profitable business. I just want to get a sense of, if you compare the new plants in China with the facilities in Europe and the U.S. in terms of size, production process, or the catalysts they use, how do they benchmark today? Are they better, and as a result able to produce at a lower cost? That's my second question. And the final one is really just a follow-up on the Nutrim project, just an update on where things stand there — has the project kicked off? Are you...

Speaker unknown
#36

Whether we're already seeing the benefits or not — thank you. Alright, thanks for those questions; they cover a range of different topics. So regarding Tayo, just understand that our thiochemical business — I'm aware that what we supply into methionine is, well, methionine is the more heavily marketed and better-known product, easier for people to track. So frequently people link Thio with methionine, yet in reality our Thio business extends well past what we provide for methionine — that's essentially a base product used by methionine customers, where we're highly competitive, and our customers too. So I'd say it's still a significant business for us — for Arkema, but sorry, let me bring the microphone nearer to you. Okay, so shall I carry on? Yes, I'm not sure. I'd say methionine stays an important business, but take DMDS, for instance, which is a considerably larger business built on sulfur — all of Arkema's sulfur chemicals and within thiochemicals — so as you said, TGS faces some challenges, and as you know we don't comment on commercial contracts or what's going on with a customer. Still, I'd say we remain quite well positioned, particularly in the market in the other region, on this base product for methionine, but as I said, Thio stays a key element of Arkema, with some very strong product lines such as DMDS and other product lines built on sulfur.

Speaker unknown
#37

The item that isn't tied to your question, though we've brought it up a number of times during this year on Tayo, is that they resemble other performance additives — definitely within Arkema, the business line, which is impacted by this Middle East situation, since we have a lot of customers in the Middle East, since we have this quite significant rise in sulfur plus other elements, so they get affected by this sort of external factor. Turning to the Bostik market, I'd say that if you set aside input cost — meaning, say, propylene or other base elements that go into the acrylics or acrylic esters — then for the processes themselves, I'd say we're fairly comparable when it comes to competitiveness across the three regions of the world. Where the difference lies — and it isn't only in acrylics, it applies to many products — is that the base raw material, so the olefin, for instance, in Asia is significantly lower than in other regions. So in the end, the cost of making acrylic, like other chemicals in the example, is by 100 in the chemical industry. Producing a product in China costs significantly less than in other parts of the world — but that's not because of the process itself, it's because of the industry.

Speaker unknown
#38

That the process employs to create the end product. But when it comes to competitiveness, we're comparable—at least for Arkema—across all three global regions. As for Nutrien, we're seeing very strong progress. We already have benefits this year, and those form part of the 50 million guidance of EBITDA—the additional EBITDA guidance tied to the major projects, since Nutrien is one of them. So the benefits are starting to show, and we should see a significant ramp up next year. From a technological standpoint, though, we've achieved a very significant improvement. I'd also like to mention that with polyamide 11, amino 11 and polyamide 11 in Singapore—another major Arkema project for anyone interested in tracking it—we've hit record production. So in terms of production, we're now really exactly where we thought we would be, which is truly rewarding the effort of our teams. Thank you so much. You're welcome.

Operator operator
#39

Our final question is from James Hooper at Bernstein — please go ahead.

James Hooper analyst
#40

Thanks so much for taking my questions. I have two remaining. The first is really a follow-on, Thierry, to what you just said. You mentioned PA11, but could you put the 50 million of EBITDA from Additional Projects this year into context? Can you give us some guidance for 2027 — what the project should be that we should be thinking about, and how the ramp-up proceeds from there? And the second question concerns leverage. It has been creeping up, rising again to, I believe, 2.8 times, as shown in the presentation. Could you just indicate the moving parts that would bring it down, which you expect to see over the coming quarters? Thank you.

Speaker unknown
#41

On the first question, that's 50 million for this year, and the ramp-up is going to keep going in the years ahead. As you know, under the normalized conditions we originally anticipated for this project, we were running at a pace of more than 100 per year. In the kind of macro environment we have now, we're closer to 50-60. We did 60 last year. This year, it should be 50. So it will depend, and it's too early for us to have that visibility — for you as well — looking at next year. It depends on what the macro will be next year. I'd say if the macro continues as it is, we should add roughly 50 million, and that's the addition for next year coming from this major project under this kind of macro. Should the macro improve, then it could reach 60, 70, 80. What's certain is that in the end, we intend to add, relative to the end of 24, the 400 million that we have defined. I think the long-term target remains unchanged. It's simply that the pace is slower than expected, but it's still a pretty good contribution year after year.

Speaker unknown
#42

On the leverage ratio — Marie-Josée, would you like to weigh in? On leverage, when you actually take a look at it,.

Marie-José Donsion executive
#43

It's not much different from where leverage stood at the same point a year ago. The real story is really inflation's effect on working capital, plus the way working capital itself swings seasonally across the quarters. As you're aware, our Q4 is usually quite favorable when it comes to working cap variance, which can produce cash and bring the ratio down. So by year end I'm definitely expecting the ratio to be a bit better.

Operator operator
#44

Thanks. This is Kepler Cheuvreux. Go right ahead.

Christian Faitz analyst
#45

Yes, I appreciate you fitting me in. Could you put a number on the energy cost bill for this year and explain your hedging position? And second, the EU Commission plans to shield the chemical industry from unfair competition—particularly from Asia—through tariffs and quotas. I’m not referring to fluorgas here, but to other products. What’s your view on that?

Speaker unknown
#46

On that question, we do have a perspective regarding EU protection. So when it comes to energy cost, as you're aware, we sit at between — I'd put it this way: first off, energy represents roughly 6%, 7% of the variable cost total for us. Of that, I'd say... half comes from nat gas and half from electricity. Electricity is mainly consumed in Europe, whereas nat gas is distributed more broadly across the world. On electricity in Europe, we can state that we're nearly 100% or at least 80%. OK, so we're fairly hedged there. That gives us a natural hedge. I'd say under our hedging policy, we treat the biggest portion of the hedge as being on electricity; on nat gas we hedge in part, okay, but under 50 — yet overall, on the whole energy cost of arkema, I'd say we're hedged at a good 50 percent at minimum, I'd say, if electricity and nat gas are both included, and the picture differs by region. Okay. And regarding EU protection, it's handled case by case. For instance, as you know, we have an anti-dumping case on acrylics. It truly hinges on the situation — there are various routes to local content as well, depending on which part of the EU is involved.

Speaker unknown
#47

That works for some applications, so it's hard to settle on a single position there. What's evident is that awareness has grown within the EU that we can't simply let Europe open up easily on every product — it has to be handled case by case. There's no single answer. The response needs to differ depending on the chemical product line. So as far as Arkema is concerned — and we don't state this publicly — there are a few instances where we feel it isn't tolerable on our side in Europe. It isn't universal, but it applies at certain sites where we believe competition isn't fair and Europe must safeguard its industrial plants. And we view that as a problem of global scope. As you know, we operate very globally, but it also matters to try to safeguard the site that genuinely merits protection, because the competition there isn't on equal footing. Thank you. You're welcome.

Operator operator
#48

Mr. Lourenco, at this point we don't have any further questions queued up.

Speaker unknown
#49

Alright, thanks to everyone for listening and for the great questions. As always, if you'd like to dig deeper into anything in the release, the IR team is available to help. Thanks a lot. Have a good day.

Operator operator
#50

Thanks, everyone, for being with us. That brings the conference to a close. You’re free to hang up your phones now. Appreciate it. This live transcript is produced automatically, with no human involvement or review. The call has concluded. This live transcript is produced automatically, with no human involvement or review.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Arkema S.A. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to Arkema S.A. earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.